Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma - Wikidata - wikimedia - TriplyDB

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

http://www.wikidata.org/entity/Q33990834

about

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Tumor refractoriness to anti-VEGF therapy The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Recurrent Glioblastoma: Where we stand Development of targeted therapies in treatment of glioblastoma Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Cancer imaging by optical coherence tomography: preclinical progress and clinical potential.Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets Circulating glioma biomarkers Twisted tango: brain tumor neurovascular interactions Spinal cord tumours: advances in genetics and their implications for treatment Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches Brain tumor stem cells: Molecular characteristics and their impact on therapy Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone Metabolic impact of anti-angiogenic agents on U87 glioma cells Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas It is time to include patients with brain tumors in phase I trials in oncology Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Angiogenic inhibition in high-grade gliomas: past, present and future.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Blood-based biomarkers for malignant gliomas Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma Imaging biomarkers for antiangiogenic therapy in malignant gliomas.The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Bevacizumab for acute neurologic deterioration in patients with glioblastoma.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

P2860

Q24616631-33CE31F7-04C8-489C-9702-91DC3F56FB4B Q26746067-148BB0FA-498C-46B9-8C7E-3E4333348CA4 Q26747678-8BDC116F-4882-45FF-88D7-7594CAD1FEE1 Q26752321-3AA66BF6-5776-4011-9646-8C8468B3BF98 Q26765042-EBE568C3-CA6E-48B8-88EF-1EC0EB5E12D5 Q26778787-ABFD2F10-1ED7-40C8-87DD-820650B1397C Q26799458-C5A670CC-C5B9-420E-81EA-95C508AE1C0A Q26822717-02B17F51-B333-4C12-A6A0-4FA00B884513 Q26823084-D87F06D7-1F9F-4A41-8290-07AD6EA01015 Q26824557-37D8D6C1-FC5C-4A6B-A845-7486C4531247 Q26829873-AB67D09C-6B21-4204-9D42-BCA90D662ED9 Q26830329-1D39746D-400A-435C-A3BA-3956D21A7FFD Q26849613-1EC66F2E-50FD-4143-9D8E-F0C72CDD1440 Q26851596-609FCED4-3A7E-423F-9F2E-907A93649019 Q26865120-DC61436E-7CA2-49FB-B325-22C8E3813D2A Q27003138-0D592FC9-94D7-4DDD-AFE4-E6299E25C776 Q27021470-E9BC6243-3255-47F5-B0F1-21F00410778B Q27022941-41D6106B-BA3B-497D-A85C-C82155043A66 Q27852713-602A5102-190A-40B6-A36E-145ED61A373C Q27853354-8A7C8261-B33C-452E-BD7E-3E44BEDD1351 Q27853358-95FD7DC6-D52E-47B0-9233-60A7348F529C Q28251767-D979D732-20BE-4B47-AE1A-B8258394B8A5 Q28539644-818F0663-7D08-4B95-B86F-7828E65D0B90 Q28732214-8076A93A-9C2B-4FF4-B1CE-E47E7FF81FC2 Q30300114-71141B9D-0407-47C6-9D6C-51CB31945002 Q30359059-5329130C-8CD2-493B-A19F-CEDEA469A3ED Q30359570-74A2AA58-2371-408B-90A0-049FAD4ED993 Q30417015-F6E5E3D4-D306-4857-97F0-4B1BBBB67BD8 Q30455596-24B8F630-0E24-43B2-BA92-E85759A9FA66 Q30469815-279F39DE-277A-4E03-A7CB-833F0DB23025 Q30471456-291D1860-DF42-489E-AFF1-8257CC60F012 Q30542073-A19D86C1-00A2-42A2-AB9E-1D352004A562 Q30616602-5143D468-F474-4BC3-B7FF-277071562884 Q30625411-29BAD725-0AAF-4907-8C43-FDBC39F72A3E Q30661157-D8D5B81F-08F3-444D-8470-5276BFA283D7 Q30764736-5C87598E-BDF0-4216-96AB-6BA20EB8E83A Q30797166-71B9C1E6-40B1-40C2-97BC-7E207AD53E01 Q30838127-3A7DEEDD-A7A9-4D86-8B58-29D920A8E40D Q30847284-9ABD4783-4868-4725-B120-6FBBAD3258AD Q30907831-6B869061-FE7E-42B1-A6E7-A796F3B9CBED

P2860

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

http://www.wikidata.org/entity/Q33990834

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@ast

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@en

type

label

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@ast

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@en

prefLabel

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@ast

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@en

P1433

Q33990834-1F688C94-8155-4A94-A04C-AA8CA3B69566

P1476

Q33990834-7D0C0964-31E0-4FC4-A86B-38D7DF4BA189

P2093

Q33990834-0A4484C3-F2BF-4B4C-9AA0-50349BF8ADA6

Q33990834-0A8E3506-D951-42EC-9517-244095ADA1CE

Q33990834-194A34B5-17A5-45CC-913B-F7F8EB44F1D8

Q33990834-212726C7-F2B4-46AF-A631-AF3AF8D14C75

Q33990834-3A9DFE34-A7CA-4508-B3D2-493E38E5C54D

Q33990834-4193DA6E-B263-4170-940E-580E2B01147B

Q33990834-575D6B63-A571-4CC7-8CEE-E7AE1DE5BF5E

Q33990834-60FFB4B8-84CF-41AF-8E66-BBF4E1BE3410

Q33990834-698000DE-698D-4A02-BCAB-503A90F86790

Q33990834-6DBF47E0-07E3-48C5-A543-DE630B8BD5FB

P2860

Q33990834-070DB5E1-1125-42B7-AAB1-E385221A2CF2

Q33990834-0FB1D045-9BA9-4855-8A8A-54602E2C11BC

Q33990834-1ED9D4FE-DA87-4129-8E4A-0FD7E63B61B5

Q33990834-2B311854-7485-495F-9AA0-4ABAB5782BBF

Q33990834-2EC3AC74-8205-429D-8E8F-B510DF0E26E3

Q33990834-2FDDF015-1346-4753-A0C0-000771F126E2

Q33990834-3AAC6846-2735-4111-B3B4-433F83C6A5CE

Q33990834-3C2BDA3E-BA80-41C2-9294-E36D33301359

Q33990834-3E7C8254-36E6-47D9-BD7A-77BFD8E942AA

Q33990834-4F802F8C-F40D-4517-8AD7-00930691DF98

P304

Q33990834-2FE3B0BA-34CE-4585-97A1-9D8C5E4539AD

P31

Q33990834-EB0E5F56-58D9-4390-B3A3-CBC807E19E3C

P356

Q33990834-499AE168-7A4C-4F31-B6D2-C3D1F2795B94

P407

Q33990834-197162F2-AF2F-4790-830F-3682F5E57E65

P433

Q33990834-BAAE6672-AA51-41C1-AD3E-B06C0BF976D6

P478

Q33990834-B2D7B13D-9FAF-4B36-B282-3A897E45F660

P577

Q33990834-67436421-5840-4E09-AA4A-150E532C1C2B

P698

Q33990834-5F39CDAD-EE32-4067-91DF-6CA0033D1321

P921

Q33990834-A304EE80-EFD5-4BDE-B1D5-CB96E30FED9A

P932

Q33990834-4FB80DEA-373F-49BE-888A-84CDC072D460

P356

JCO.2009.26.3988

P1433

Journal of Clinical Oncology

P1476

Phase II study of cediranib, a ...... ts with recurrent glioblastoma

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Alexis Exarhopoulos

http://www.w3.org/2001/XMLSchema#string

April F Eichler

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

David N Louis

http://www.w3.org/2001/XMLSchema#string

Elizabeth Gerstner

http://www.w3.org/2001/XMLSchema#string

Emmanuelle di Tomaso

http://www.w3.org/2001/XMLSchema#string

Fred H Hochberg

http://www.w3.org/2001/XMLSchema#string

Houng Chea

http://www.w3.org/2001/XMLSchema#string

Jan Drappatz

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Response criteria for glioma.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

P304

2817-2823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.3988

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20458050

http://www.w3.org/2001/XMLSchema#string

P921

P932

2903316

http://www.w3.org/2001/XMLSchema#string